Stability-indicating HPLC-DAD methods for determination of two binary mixtures:Rabeprazole sodium-mosapride citrate and rabeprazole sodium-itopride hydrochloride

Two selective stability-indicating HPLC methods are described for determination of rabeprazole sodium （RZ）-mosapride citrate （MR） and RZ-itopride hydrochloride （IO） mixturcs in the presence of their ICH-stress formed degradation products. Separations were achieved on X-Bridge CI 8 column using two mobile phases： the first for RZ-MR mixture consisted of acetonitrile： 0.（125 M KH,PO4 solution： TEA （30：69：1 v/v; pH 7.0）; the second for RZ-IO mixture was at ratio of 25：74：1 Iv/v： pH 9.25J. The detection wavelength was 283 nm. The two methods were validated and wdidation acceptance criteria were met in all cases. Peak purity testing using contrast angle theory, relative absorbance and log A versus the wavelengths plots were presented. The % recoveries of the intact drugs were between 99.1% and 102.2% with RSD% values less than 1.6%. Application of the proposed HPLC methods indicated that the methods could be adopted to follow the stability of their formulations.

胃肠道动力药联用黛力新治疗功能性消化不良的对比研究

目的评价依托必利、莫沙必利、多潘立酮联用黛力新治疗功能性消化不良(FD)的疗效。方法 130例确诊的FD患者随机分为3组,依托必利治疗组50例,依托必利50 mg,tid,黛力新1片,bid;莫沙必利对照组(Ⅰ组)40例,莫沙必利5 mg,tid,黛力新1片,bid;多潘立酮对照组(Ⅱ组)40例,多潘立酮10 mg,tid,黛力新1片,bid。疗程均为4周。观察患者服药前及服药1周、4周后嗳气、烧心、上腹部饱胀等症状的消失情况并做对比分析。结果治疗1周后嗳气、烧心和上腹部饱胀症状的消失率,治疗组分别为60%、56%,对照Ⅰ组为30%、35%,对照Ⅱ组为25%、25%。治疗组与各对照组之间的差异比较均有显著性(P<0.05)。治疗4周后治疗组的嗳气、烧心和上腹部饱胀症状的消失率为88%、84%,对照Ⅰ组为40%、45%,对照Ⅱ组为25%、30%,治疗组与各对照组之间的差异比较均有非常显著性(P<0.01)。结论依托必利联用黛力新改善FD患者嗳气、烧心、上腹部饱胀症状的效果最满意,可以作为治疗FD患者的首选药物。